BMJ  2006;333:559-560 (16 September), doi:10.1136/bmj.38971.587222.AB

Editorial

Extensively drug resistant tuberculosis

A serious wake-up call for global health

The first 150 words of the full text of this article appear below.

Tuberculosis outbreaks in the developed world are newsworthy.¹ However, in the developing world, where deaths from tuberculosis are common, it takes something exceptional for an outbreak to attract much attention. In response to a recent report at the 16th international AIDS conference² and to increasing South African media reports, the World Health Organization last week expressed concern about extensively drug resistant tuberculosis (also referred to as "XDR tuberculosis").³

Among 536 culture confirmed cases of tuberculosis at a rural hospital in South Africa, 41% were multidrug resistant,² defined as resistance to rifampicin and isoniazid (two key first line drugs). This is cause enough for concern as multidrug resistant tuberculosis has a worse outcome and its management is very difficult even in high resource settings.⁴ Even more alarming was that 53 (24%) of the isolates from multidrug resistant tuberculosis fulfilled the definition of extensively drug resistant tuberculosis²—namely, multidrug resistant tuberculosis . . . [Full text of this article]

Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa
(stevelawn@yahoo.co.uk)

Institute of Infectious Disease and Molecular Medicine, University of Cape Town

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Extensively drug resistant tuberculosis: Beware patients lost to follow-up

Ulf R Dahle
BMJ 2006 333: 705. [Extract] [Full Text]

Extensively drug resistant tuberculosis: Problem will get worse in South Africa unless poverty is alleviated

Solomon R Benatar
BMJ 2006 333: 705. [Extract] [Full Text]

Experts devise strategy to fight new TB strain

Peter Moszynski
BMJ 2006 333: 566. [Extract] [Full Text] [PDF]

TB in Leicester: out of control, or just one of those things?

John M Watson and Fiona Moss
BMJ 2001 322: 1133-1134. [Extract] [Full Text] [PDF]

Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus"

Paul Farmer and Jim Yong Kim
BMJ 1998 317: 671-674. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Velayati, A. A., Masjedi, M. R., Farnia, P., Tabarsi, P., Ghanavi, J., ZiaZarifi, A. H., Hoffner, S. E. (2009). Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli: Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains in Iran. Chest 136: 420-425 [Abstract] [Full text]  
• Hatherill, M, Hawkridge, T, Zar, H J, Whitelaw, A, Tameris, M, Workman, L, Geiter, L, Hanekom, W A, Hussey, G (2009). Induced sputum or gastric lavage for community-based diagnosis of childhood pulmonary tuberculosis?. Arch. Dis. Child. 94: 195-201 [Abstract] [Full text]  
• Sun, Z., Chao, Y., Zhang, X., Zhang, J., Li, Y., Qiu, Y., Liu, Y., Nie, L., Guo, A., Li, C. (2008). Characterization of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates in China. J. Clin. Microbiol. 46: 4075-4077 [Abstract] [Full text]  
• Villar, R., Vicente, E., Solano, B., Perez-Silanes, S., Aldana, I., Maddry, J. A., Lenaerts, A. J., Franzblau, S. G., Cho, S.-H., Monge, A., Goldman, R. C. (2008). In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J Antimicrob Chemother 62: 547-554 [Abstract] [Full text]  
• Vicente, E., Villar, R., Burguete, A., Solano, B., Perez-Silanes, S., Aldana, I., Maddry, J. A., Lenaerts, A. J., Franzblau, S. G., Cho, S.-h., Monge, A., Goldman, R. C. (2008). Efficacy of Quinoxaline-2-Carboxylate 1,4-Di-N-Oxide Derivatives in Experimental Tuberculosis. Antimicrob. Agents Chemother. 52: 3321-3326 [Abstract] [Full text]  
• Newsom, S. (2006). The history of infection control: Tuberculosis: part two Finding the cause and trying to eliminate it. British Journal of Infection Control 7: 8-11  
• Pratt, R. (2006). Behold a pale horse: confronting 21st century plagues. British Journal of Infection Control 7: 10-13 [Abstract]  
• Dahle, U. R (2006). Extensively drug resistant tuberculosis: beware patients lost to follow-up.. BMJ 333: 705-705 [Full text]  
• Benatar, S. R (2006). Extensively drug resistant tuberculosis: problem will get worse in South Africa unless poverty is alleviated.. BMJ 333: 705-705 [Full text]  

Rapid Responses:

Read all Rapid Responses

XDR-TB in low-incidence countries

Ulf R. Dahle
bmj.com, 16 Sep 2006 [Full text]

Why multi-drug resistant tuberculosis will get worse in South Africa

Solomon R Benatar
bmj.com, 18 Sep 2006 [Full text]

Is it XDR in KwaZulu Natal?

Panganai Dhliwayo
bmj.com, 26 Sep 2006 [Full text]

IDPF-UNITAID Support for MDR-TB Urgently Needed

Thelma E Tupasi, et al.
bmj.com, 29 Sep 2006 [Full text]

Managing XDR TB in India: an uphill task

Uday A Gupta
bmj.com, 10 Oct 2006 [Full text]

Online poll

Find out more here>> and here>>